Logo
T

Telesis Bio

54 employees

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity’s greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio's technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

Investor insights

Funding rounds participated in

$74M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology

Sectors

Biotechnology

Date founded

2013

Funding rounds raised

Total raised

$74M

from 2 investors over 1 rounds

T

Telesis Bio raised $74M on July 1, 2023

Investors: Novalis LifeSciences and + 2 Other investors

FAQ